Tardive Dyskinesia Medications: What to Check Before Changing Treatment
If new lip smacking, tongue movements, blinking, or restless limb motions start after months or years on an antipsychotic or metoclopramide, one common mistake is changing the medication too quickly before a clinician reviews whether it may be tardive dyskinesia.
Tardive dyskinesia, often shortened to TD, can affect speech, eating, confidence, and daily function, so the earlier it is recognized, the more options you may have to limit its impact.
This guide explains which medications can cause tardive dyskinesia, who is at higher risk, how TD is diagnosed, and which treatment options are commonly used. It is educational only and is not a substitute for medical advice.
When repetitive movements may be tardive dyskinesia
TD is a movement disorder linked mainly to dopamine receptor-blocking agents, often called DRBAs. These medicines include many antipsychotics and some drugs used for nausea or gastrointestinal problems.
Common signs include lip smacking, chewing motions, tongue protrusion, grimacing, frequent blinking, rocking, and irregular movements of the arms or legs. A basic overview is available from MedlinePlus, and a more detailed clinical summary appears in StatPearls.
TD does not always appear right after a medication starts. In many cases, risk rises with longer exposure, higher cumulative dose, or repeated use over time.
Medications that can cause tardive dyskinesia
No dopamine-blocking drug is completely risk-free, even though some newer agents may carry a lower TD risk than older ones. The decision is usually not just which drug you take, but how long you have taken it, at what dose, and whether you have had other movement side effects before.
| Medication or class | What to review before changing treatment |
|---|---|
| Haloperidol (Haldol) | A first-generation antipsychotic with well-known TD risk, especially with long-term exposure. Review your dose, how long you have used it, and any earlier stiffness, tremor, or akathisia; drug details are listed on MedlinePlus. |
| Fluphenazine | Another older antipsychotic that may carry significant TD risk, particularly at higher doses or with prolonged use. It can help to review both oral and injectable use with your prescriber; medication information appears on MedlinePlus. |
| Risperidone (Risperdal) | A second-generation antipsychotic that may have a lower TD risk than some older drugs, but TD still occurs. Review your current dose, any recent dose increases, and how symptoms changed over time; see MedlinePlus. |
| Olanzapine (Zyprexa) | This second-generation antipsychotic has documented TD cases, especially with longer use. It is worth reviewing whether metabolic issues, sedation, or dose history complicate the decision to switch; details are on MedlinePlus. |
| Metoclopramide (Reglan) | This anti-nausea and GERD medicine has a boxed warning for tardive dyskinesia. If you have used it beyond short-term treatment, ask for a medication review and read the FDA safety page. |
Other medicines can also contribute, including prochlorperazine and some long-acting injectable antipsychotics. If you are unsure which medications count as dopamine-blocking agents, ask your clinician or pharmacist to review every prescription, as-needed medicine, and over-the-counter product you use.
Who may be at higher risk for TD
Risk is not the same for every patient. A few factors tend to come up often in TD discussions:
- Longer duration of treatment with antipsychotics or other DRBAs
- Higher doses or repeated dose increases over time
- Older age, especially over 55
- Female sex
- Diabetes, prediabetes, or metabolic syndrome
- Mood disorders or a history of substance use
- Earlier extrapyramidal symptoms such as drug-induced parkinsonism or akathisia
These factors do not mean TD will happen. They do mean regular screening may matter more.
How TD is diagnosed and monitored
TD is a clinical diagnosis, which means the pattern of movements and your medication history matter more than a single blood test or scan. The main question is whether the movements fit TD after exposure to a dopamine-blocking drug.
Many clinicians use the Abnormal Involuntary Movement Scale, or AIMS, to screen for TD and track severity over time. You can view the form here: AIMS tool.
If you take a DRBA, ask how often you should be screened. Many practices check at baseline and then every 3 to 6 months, though timing can vary by diagnosis, dose, and risk factors.
Between visits, short phone videos or mirror checks may help you notice subtle changes earlier. This can be especially useful when movements are intermittent or more obvious to family members than to you.
Treatment options that may help
Do not stop the medication on your own
For some patients, the medicine linked to TD is also essential for psychiatric stability or control of severe nausea. Stopping suddenly can create other risks, so the first step is usually a supervised medication review.
Depending on the situation, a prescriber may discuss dose reduction, slower titration, or discontinuation of the suspected drug. The tradeoff is that symptom control for the original condition still needs to be protected.
Switching strategies may be considered
If the current antipsychotic seems to be contributing, some patients may be candidates to switch to a drug with a lower TD risk profile. That decision usually depends on diagnosis, past response, side effects, and relapse risk.
Clozapine is one option clinicians may consider in selected cases. Its uses and safety details are explained on MedlinePlus.
VMAT2 inhibitors are commonly used for persistent TD
Valbenazine and deutetrabenazine are FDA-approved VMAT2 inhibitors for tardive dyskinesia. These medicines can reduce involuntary movements by lowering excessive dopamine release from nerve terminals.
- Valbenazine (Ingrezza) may be convenient for patients who prefer once-daily dosing; common side effects can include sleepiness and dry mouth. Read more on MedlinePlus.
- Deutetrabenazine (Austedo) is typically taken more than once daily and may require monitoring for somnolence or mood changes. Details are available on MedlinePlus.
Guideline summaries generally support VMAT2 inhibitors as effective treatment options for TD. One practice guideline summary is available through PubMed.
Other therapies may help in specific cases
- Botulinum toxin injections may be considered for focal movements that affect the jaw, eyelids, or another specific area.
- Physical, occupational, or speech therapy may help when TD affects posture, gait, swallowing, or communication.
- Medication review can uncover contributors such as stimulants, poor sleep, or other drugs that may worsen visible movements.
- Anticholinergics such as benztropine may help some other movement side effects but can sometimes worsen TD.
Questions to ask before you agree to a treatment change
- Do my movements look more like TD, akathisia, parkinsonism, or something else?
- Which medication is the most likely cause, and how strong is the evidence?
- What happens to my original condition if we lower the dose or switch drugs?
- Would VMAT2 inhibitors fit my situation, side-effect history, and insurance coverage?
- How often should I have AIMS screening?
- Should I keep short videos or a symptom diary between visits?
When urgent evaluation matters
Some symptoms need faster attention because they may point to something other than routine TD or to a serious complication. Seek urgent care if movements rapidly worsen or start affecting breathing, swallowing, or safe walking.
- Severe neck or jaw spasms
- High fever, confusion, or marked muscle rigidity
- Thoughts of self-harm or harm to others
Practical support and next steps
If you think a medication may be causing tardive dyskinesia, bring a full medication list to your next visit and note when the movements began. Include as-needed medicines, nausea drugs, injections, and any recent dose changes.
It may also help to keep your sleep, hydration, caffeine use, and blood sugar management as steady as possible, since these factors can affect how noticeable movements feel. For patient education and support resources, visit NAMI.
The main goal is not simply to stop a medicine quickly. It is to balance psychiatric or gastrointestinal treatment needs with TD control, monitoring, and quality of life.